Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) has received a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokers that […]
Susquehanna International Group LLP boosted its position in Jounce Therapeutics, Inc. (NASDAQ:JNCE – Get Rating) by 824.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 29,292 shares of the company’s stock after buying an additional 26,125 shares during the period. Susquehanna International Group LLP’s holdings in Jounce Therapeutics were worth $33,000 as of its […]
StockNews.com began coverage on shares of Jounce Therapeutics (NASDAQ:JNCE – Get Rating) in a research note published on Saturday. The brokerage issued a hold rating on the stock. JNCE has been the subject of several other reports. Sumitomo Mitsui Financial Group reissued a neutral rating on shares of Jounce Therapeutics in a research report on […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.